Important Information Regarding Vyzulta

Posted in Latest News on March 16, 2018.

During the March 9, 2018 Board of Optometry meeting, the board approved for addition to Rule 64B13-18.002 Formulary of Topical Ocular Pharmaceutical Agents, Vyzulta (latanoprostene bunod ophthalmic solution) 0.024%.

Important note, Vyzulta, at this time, cannot be prescribed by certified Optometrists in Florida until the rule has been approved. Once the rule has gone through the approval process, notice will be provided on this site, and at that time Vyzulta may be prescribed by certified optometrists.

 



More Latest News

Important Information Regarding Rhopressa
June 26, 2018

Click here to find out more about Rule 64B13-18.002 formulary of Topical Ocular Pharmaceutical Agents, Rhopressa (netarsudil ophthalmic solution) 0.02%.) Continue reading


Third Quarterly Performance Report Released for the 2017-2018 Fiscal Year
June 8, 2018

The Quarterly Performance Report for the third quarter of the 2017-2018 fiscal year is now available online. Continue reading